Diagnostic applications of nuclear medicine: Lymphomas

Heather A. Jacene, Sree Harsha Tirumani, Richard L. Wahl

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/ necrosis in residual masses. Posttherapy [18F] FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in setting of clinical trials.

Original languageEnglish
Title of host publicationNuclear Oncology
Subtitle of host publicationFrom Pathophysiology to Clinical Applications
PublisherSpringer International Publishing
Pages353-393
Number of pages41
ISBN (Electronic)9783319262369
ISBN (Print)9783319262345
DOIs
StatePublished - Oct 27 2017

Keywords

  • Hodgkin
  • Lymphoma
  • Response to therapy
  • Staging
  • [F]FDG
  • [F]FDG-PET/CT
  • non-Hodgkin

Fingerprint Dive into the research topics of 'Diagnostic applications of nuclear medicine: Lymphomas'. Together they form a unique fingerprint.

Cite this